Literature DB >> 26841691

Connective tissue diseases: Nucleosomes and systemic sclerosis.

Steven O'Reilly1, Jacob M van Laar2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26841691     DOI： 10.1038/nrrheum.2016.9

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 2.  Role of innate immune system in systemic sclerosis.

Authors:  Nicola Fullard; Steven O'Reilly
Journal:  Semin Immunopathol       Date:  2015-07-10       Impact factor: 9.623

Review 3.  Current frontiers in systemic sclerosis pathogenesis.

Authors:  Marzena Ciechomska; Jacob van Laar; Steven O'Reilly
Journal:  Exp Dermatol       Date:  2015-03-27       Impact factor: 3.960

4.  Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity.

Authors:  Z Amoura; J C Piette; H Chabre; P Cacoub; T Papo; B Wechsler; J F Bach; S Koutouzov
Journal:  Arthritis Rheum       Date:  1997-12

Review 5.  The Role of Cell Death in the Pathogenesis of SLE: Is Pyroptosis the Missing Link?

Authors:  M Magna; D S Pisetsky
Journal:  Scand J Immunol       Date:  2015-09       Impact factor: 3.487

6.  Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.

Authors:  Steven O'Reilly; Marzena Ciechomska; Rachel Cant; Jacob M van Laar
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

7.  Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells.

Authors:  Ayumi Yoshizaki; Takashi Taniguchi; Ryosuke Saigusa; Takemichi Fukasawa; Satoshi Ebata; Hiroko Numajiri; Kouki Nakamura; Takashi Yamashita; Takehiro Takahashi; Tetsuo Toyama; Yoshihide Asano; Thomas F Tedder; Shinichi Sato
Journal:  Ann Rheum Dis       Date:  2015-11-13       Impact factor: 19.103

8.  Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.

Authors:  Silvia L Bosello; Giacomo De Luca; Manuela Rucco; Giorgia Berardi; Matteo Falcione; Francesco Maria Danza; Tommaso Pirronti; Gianfranco Ferraccioli
Journal:  Semin Arthritis Rheum       Date:  2014-09-08       Impact factor: 5.532

9.  Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors.

Authors:  Marzena Ciechomska; Christiaan A Huigens; Thomas Hügle; Tess Stanly; Andreas Gessner; Bridget Griffiths; Timothy R D J Radstake; Sophie Hambleton; Steven O'Reilly; Jacob M van Laar
Journal:  Ann Rheum Dis       Date:  2012-12-06       Impact factor: 19.103
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.